Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Pharma enhances its focus on Asia-Pacific partnerships

While the Japanese market still dominates deal activities in the Asia-Pacific (APAC) region, companies and research institutes in emerging APAC countries have recently been attracting high calibre collaborators, according to the latest analysis by Datamonitor.

28 Nov 2010

Cardinal Health announces plan to acquire Kinray

Cardinal Health today announced plans to acquire Kinray, Inc., a leading pharmaceutical distributor serving the New York metropolitan area, for $1.3 billion in an all-cash transaction that will significantly expand its ability to serve retail independent pharmacies in the northeastern United States.

19 Nov 2010

FDA grants Impax final approval for generic Allegra-D ANDA

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

16 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Drug industry: Pharmaceutical companies find ways to cope as patents expire; FDA criticized for consulting contracts

There is a simple explanation for most of the mergers and acquisitions in the pharmaceutical world these days the so called Patent Cliff. Simply put, many of the drug industry's biggest earners blockbuster medications that have paid the bills for the last decade are about to lose their patent protections.

15 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

Investigations examine Medicare’s dialysis system, CT scanners and drugs

ProPublica reports on the costs and risks associated with dialysis: "In 1972, after a month of deliberation, Congress launched the nation's most ambitious experiment in universal health care: a change to the Social Security Act that granted comprehensive coverage under Medicare to virtually anyone diagnosed with kidney failure, regardless of age or income.

10 Nov 2010

First Edition: November 9, 2010

Today's news includes reports about the Supreme Court's decision regarding an early challenge to the health law.

9 Nov 2010

Teva hosts Respiratory Opportunity Meeting for financial community

Teva Pharmaceutical Industries Ltd. today hosted its Respiratory Opportunity Meeting for the financial community in New York, featuring in-depth presentations on Teva's current and future respiratory growth strategy.

8 Nov 2010

AmerisourceBergen fiscal fourth quarter revenue increases 5.3% to $19.7 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2010 fourth quarter ended September 30, 2010, diluted earnings per share increased 13.6 percent to $0.50, and revenue increased 5.3 percent to a record $19.7 billion.

2 Nov 2010

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010.

2 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

PHARMABIZ.com examines India’s push for clearer definition of counterfeit, substandard medicines

India has taken the lead to get together a number of generic drug-producing nations to call for better definitions to ensure quality, strengthening of regulatory authorities in the respective countries, and bringing focus of the world to public health instead of intellectual property, PHARMABIZ.com writes in an article that examines the recent meeting of leaders from Brazil, India and South Africa on issues regarding counterfeit medicines.

29 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

"India believes a row with the European Union over seizures of generic drugs will be settled without litigation, Trade Minister Anand Sharma said on Wednesday," Reuters reports (Lynn, 10/20).

26 Oct 2010

PhRMA representatives meet with officials in India to discuss compulsory licensing

During a visit with government officials, industry leaders and NGOs in India last week, representatives from Pharmaceutical Research and Manufacturers of America (PhRMA), a U.S. lobbying group that represents the country's pharmaceutical industry and biotechnology companies, addressed "the Indian government's proposal to allow local drugmakers to make low-cost version of patented drugs so that they can be made available to patients," the Economic Times reports.

26 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Walgreens September sales increases 5.3% to $5.64 billion

Walgreens had September sales of $5.64 billion, an increase of 5.3 percent from $5.36 billion for the same month in fiscal 2010. Duane Reade stores, acquired in April 2010, contributed 2.8 percentage points to the total sales increase for the month.

5 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010